Sagent Pharmaceuticals (SGNT) Misses Q4 EPS Views; Guides FY16 Revenue Below Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Sagent Pharmaceuticals (SGNT) Misses Q4 EPS Views; Guides FY16 Revenue Below Expectations

Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results

February 16, 2016 7:30 AM EST

Establishes Long-Term Growth Strategy to Expand Product Offerings, Enhance Operational Performance, and Execute on Strategic Acquisitions

Enters Into Agreement to Sell Sagent (China) Pharmaceuticals (SCP) Reducing Cost Structure by Approximately $10 Million Per Year

Affirms Full Year Guidance Including Revenue and Adjusted EBITDA Growth Expectations for 2016

SCHAUMBURG, Ill., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced financial results for the fourth quarter and fiscal year ended December... More